Sun Pharmaceutical Industries Limited (SUNPHARMA) — FY25 Annual Report | 4 July 2025

Sun Pharmaceutical Industries Limited's FY2024-25 annual report shows consolidated revenue of ₹25,784.4 million and net profit of ₹42,826.2 million, reflecting 9% revenue growth and 19% profit growth YoY. The company achieved 20% specialty revenue contribution (up from 9% in FY20), driven by 42 new product launches and FDA approvals including LEQSELVI™ for alopecia areata. Key growth engines include India (13.7% revenue growth), US (5.8% growth), and emerging markets (9.2% growth), with specialty medicines now representing 40% of global pharma spending. The board approved a final dividend of ₹5.50 per share (total payout: ₹13,196.34 million), while maintaining a strong $3.1 billion net cash position. Strategic priorities focus on expanding specialty pipelines (7 candidates in clinical trials), advancing digital transformation, and executing a Composite Scheme of Arrangement involving multiple subsidiaries. Governance updates include new appointments (Ms. Vidhi Shanghvi as Whole-time Director, Mr. Kirti Ganorkar as Managing Director) and board restructuring with 5 independent directors. The report underscores robust ESG commitments, including 24.69% carbon reduction (vs 35% target by 2030) and ₹508.34 million CSR spending impacting 1 million lives.